Heron Therapeutics Inc.

LSE:0J4V UK
Market Cap
$64.76 Million
Market Cap Rank
#17795 Global
#335 in UK
Share Price
$0.83
Change (1 day)
-2.47%
52-Week Range
$0.83 - $2.50
All Time High
$41.15
About

Heron Therapeutics, Inc., a commercial-stage biotechnology company, engages in developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It … Read more

Heron Therapeutics Inc. (0J4V) - Total Assets

Latest total assets as of December 2025: $670.88 Million USD

Based on the latest financial reports, Heron Therapeutics Inc. (0J4V) holds total assets worth $670.88 Million USD as of December 2025.

Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.

Heron Therapeutics Inc. - Total Assets Trend (2012–2025)

This chart illustrates how Heron Therapeutics Inc.’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.

Heron Therapeutics Inc. - Asset Composition Analysis

Current Asset Composition (December 2025)

Heron Therapeutics Inc.'s total assets of $670.88 Million consist of 35.5% current assets and 64.5% non-current assets.

Asset Category Amount (USD) % of Total Assets
Cash & Equivalents $0.00 4.3%
Accounts Receivable $89.59 Million 13.4%
Inventory $92.75 Million 13.8%
Property, Plant & Equipment $0.00 0.0%
Intangible Assets $0.00 0.0%
Goodwill $0.00 0.0%

Asset Composition Trend (2012–2025)

This chart illustrates how Heron Therapeutics Inc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.

Key Asset Composition Facts

  • Current vs. Non-Current Assets: Heron Therapeutics Inc.'s current assets represent 35.5% of total assets in 2025, a decrease from 96.6% in 2012.
  • Cash Position: Cash and equivalents constituted 4.3% of total assets in 2025, down from 95.6% in 2012.
  • Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2012.
  • Asset Diversification: The largest asset category is inventory at 13.8% of total assets.

Heron Therapeutics Inc. Competitors by Total Assets

Key competitors of Heron Therapeutics Inc. based on total assets are shown below.

Company Country Total Assets
No similar companies found.

Heron Therapeutics Inc. - Asset Efficiency Metrics

Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.

Asset Turnover Ratio

Measures how efficiently a company uses its assets to generate sales

Historical Range: 0.02 - 0.62

Lower asset utilization - Heron Therapeutics Inc. generates 0.23x its asset value in annual revenue.

Return on Assets (ROA)

Measures how efficiently a company uses its assets to generate profits

Historical Range: -256.58% - -3.01%

Negative ROA - Heron Therapeutics Inc. is currently not profitable relative to its asset base.

Heron Therapeutics Inc. - Liquidity and Working Capital Analysis

Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.

Key Liquidity Metrics

Metric Current 1 Year Ago 5 Years Ago
Current Ratio 2.48 2.29 2.70
Quick Ratio 1.51 1.70 2.28
Cash Ratio 0.00 0.00 0.00
Working Capital $141.97 Million $ 117.56 Million $ 171.37 Million

Heron Therapeutics Inc. - Advanced Valuation Insights

This section examines the relationship between Heron Therapeutics Inc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.

Key Valuation Metrics

Current Price-to-Book Ratio -
Latest Market Cap to Assets Ratio 0.17
Asset Growth Rate (YoY) 187.7%
Total Assets $670.88 Million
Market Capitalization $111.01 Million USD

Valuation Analysis

Below Book Valuation: The market values Heron Therapeutics Inc.'s assets below their book value (0.17 x), which may indicate investor concerns about asset quality or future growth.

Rapid Asset Growth: Heron Therapeutics Inc.'s assets grew by 187.7% over the past year, indicating significant expansion of the company's resource base.

Annual Total Assets for Heron Therapeutics Inc. (2012–2025)

The table below shows the annual total assets of Heron Therapeutics Inc. from 2012 to 2025.

Year Total Assets Change
2025-12-31 $670.88 Million +187.75%
2024-12-31 $233.15 Million +4.78%
2023-12-31 $222.51 Million -11.33%
2022-12-31 $250.95 Million -17.91%
2021-12-31 $305.71 Million -13.53%
2020-12-31 $353.56 Million -31.05%
2019-12-31 $512.78 Million +10.95%
2018-12-31 $462.18 Million +97.25%
2017-12-31 $234.31 Million +247.21%
2016-12-31 $67.48 Million -51.05%
2015-12-31 $137.84 Million +79.76%
2014-12-31 $76.68 Million +0.98%
2013-12-31 $75.94 Million +35.67%
2012-12-31 $55.97 Million --